NJ-LTIMINDTREE
7.5.2024 14:07:25 CEST | Business Wire | Press release
LTIMindtree [NSE: LTIM, BSE: 540005], a global technology consulting and digital solutions company, announced a collaboration with IBM to establish a global, joint Generative AI Center of Excellence (CoE) in India, a co-innovation center combining the power of the IBM watsonx AI and data platform and the engineering skills of LTIMindtree.
Open innovation drives the growth of enterprise AI technology, helping organizations apply AI-infused solutions to solve business challenges. It is this same open innovation which plays a key role in the LTIMindtree and IBM collaboration.
The LTIMindtree and IBM CoE plans to offer a comprehensive suite of services, combining LTIMindtree's expertise in data and machine learning model customization and full-stack engineering with IBM watsonx technology including watsonx.ai, watsonx.data, and watsonx.governance, and AI assistants. The center, located in India, will focus on building point solutions to accelerate clients’ generative AI adoption journeys.
Nachiket Deshpande, COO and Whole-time Director, LTIMindtree, commenting on the collaboration, said, “Open innovation is the cornerstone of progress in the digital era. By joining forces with IBM, LTIMindtree aims to be at the forefront of advancing AI technologies and empowering businesses to achieve unparalleled success with governance.”
Kate Woolley, General Manager, IBM Ecosystem said, “IBM Service Partners such as LTIMindtree play an integral role helping enterprises maximize the benefits of generative AI technology through all phases of their AI adoption journey. Our collaboration, distinguished by the Center of Excellence, is an opportunity for our companies to work closely together to help funnel the latest AI research and innovations into technologies solving real-world business challenges.”
This collaboration is expected to offer various benefits to clients, including providing them access to the following:
- IBM watsonx.governance: LTIMindtree will offer a watsonx.governance integration with the Canvas.ai platform, resulting in a collaborative enterprise-ready toolkit that enables organizations to strategically incorporate AI governance frameworks throughout the entire AI lifecycle. Together, these platforms will provide users with the structure and processes necessary to help them navigate the complexities of the regulatory landscape while also adhering to ethical standards, compliance requirements, and responsible AI practices.
- IBM watsonx.data: The CoE will also offer an enterprise data modernization and warehouse augmentation service powered by watsonx.data. This service will provide the framework and tools for data warehouse consumers to augment the performance of their existing data warehouse capabilities using the power of IBM watsonx.data and LTIMindtree's expertise in crafting tailored solutions.
- IBM watsonx.ai: The CoE is also expected to provide a suite of services dedicated to modernizing full-stack applications across a set of domain specific use cases, including mainframe application modernization use cases. LTIMindtree's proficiency in full-stack engineering, combined with the powerful IBM watsonx.ai studio, will help enterprises train, validate, tune and deploy AI models while simplifying their modernization efforts.
The Center of Excellence aims to play a pivotal role in expanding the scope of generative AI applications for digital initiatives of clients, utilizing the IBM watsonx platform and AI assistants, machine learning, speech recognition, natural language processing, and conversational AI to augment end user experience.
Clients interested in learning more about this collaboration can meet LTIMindtree at IBM THINK in Boston. For more information on LTIMindtree’s offerings with IBM, please visit https://www.ltimindtree.com/enterprise-solutions/ibm/
About LTIMindtree
LTIMindtree is a global technology consulting and digital solutions company that enables enterprises across industries to reimagine business models, accelerate innovation, and maximize growth by harnessing digital technologies. As a digital transformation partner to more than 700 clients, LTIMindtree brings extensive domain and technology expertise to help drive superior competitive differentiation, customer experiences, and business outcomes in a converging world. Powered by 81,000+ talented and entrepreneurial professionals across more than 30 countries, LTIMindtree — a Larsen & Toubro Group company — combines the industry-acclaimed strengths of erstwhile Larsen and Toubro Infotech and Mindtree in solving the most complex business challenges and delivering transformation at scale. For more information, please visit https://www.ltimindtree.com/.
About IBM
IBM is a leading provider of global hybrid cloud and AI, and consulting expertise. We help clients in more than 175 countries capitalize on insights from their data, streamline business processes, reduce costs and gain the competitive edge in their industries. More than 4,000 government and corporate entities in critical infrastructure areas such as financial services, telecommunications and healthcare rely on IBM's hybrid cloud platform and Red Hat OpenShift to affect their digital transformations quickly, efficiently and securely. IBM's breakthrough innovations in AI, quantum computing, industry-specific cloud solutions and consulting deliver open and flexible options to our clients. All of this is backed by IBM's long-standing commitment to trust, transparency, responsibility, inclusivity and service.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240506254574/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Echodyne Opens New Manufacturing Facility to Meet Surging Global Demand for Advanced MESA® Radar9.7.2026 15:00:00 CEST | Press release
New Washington State facility provides capacity to manufacture more than 30,000 radars annually, strengthening the U.S. defense industrial base As governments around the world accelerate investment in counter-unmanned aircraft systems (C-UAS) and short-range air defense, Echodyne today announced the opening of a new advanced radar manufacturing facility in Washington State, significantly expanding its manufacturing capacity to meet rapidly growing demand from U.S. and allied customers. With millions of drones manufactured and used by both sides in the Russian War in Ukraine, the need for enhanced safety for defense, national security, and critical infrastructure assets grows with every successful strike and interception. The low cost and high utility of drones dramatically alters the need for safety and security sensors. And as the low altitude economy takes off, hundreds of thousands of drones will perform a range of life-saving and commercial missions, requiring a sensor infrastructu
Orca Security Report: 99.9% of Fixable AI Vulnerabilities Remain Unpatched as AI Moves Into Production9.7.2026 15:00:00 CEST | Press release
Analysis of more than 1,200 production cloud environments provides a first-hand view into how organizations are embedding AI into business-critical workflows, exposing new security risks that traditional controls weren't built to address. Orca Security, a leader in cloud and AI security, today released its 2026 State of AI Security Report, offering a first-hand view into how AI is being deployed across more than 1,200 production cloud environments. The findings show AI is no longer limited to isolated pilots or developer experiments. Organizations are embedding AI into production applications, cloud services, and autonomous workflows faster than security programs can adapt. More than half (56%) of organizations have already deployed AI agents into production, while 51% use AI to build custom applications. At the same time, Orca found that 81% of organizations run vulnerable AI packages, and 99.9% of fixable AI vulnerabilities remain unpatched, highlighting how quickly AI has become ope
Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration9.7.2026 15:00:00 CEST | Press release
Cortechs.ai and Viz.ai partner to tackle multiple sclerosis and other neurodegenerative diseases across Viz.ai's health system network Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with Cortechs.ai, a global leader in neuroimaging and quantitative analysis solutions, to integrate Cortechs.ai's NeuroQuant and NeuroQuant MS suite into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the U.S. This partnership marks Viz.ai's expansion into neurodegenerative disease, growing Viz Neuro Suite beyond its already market-leading neuro offerings. The collaboration will begin with a focus on multiple sclerosis (MS), integrating quantitative MRI analysis from NeuroQuant MS directly into Viz.ai's care coordination workflow, giving clinicians both the quantitative precision and the coordination infrastructure needed to identify and manage MS patients at scale. “Viz.ai's co
SCP Standard Capital Partners AG: Fabian Becker Appointed Chairman of the Management Board and CEO9.7.2026 14:51:00 CEST | Press release
The Supervisory Board of SCP Standard Capital Partners AG (WKN: A12UPJ | ISIN: DE000A12UPJ7 | XETRA ticker: CAP) resolved today to appoint Mr. Fabian Becker as Chairman of the Management Board and Chief Executive Officer (CEO), effective as of 9 July 2026. Ms. Stephanie Schettler-Köhler will remain a member of the Management Board and will assume the role of Chief Operating Officer (COO). View source version on businesswire.com: https://www.businesswire.com/news/home/20260709982268/en/
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis9.7.2026 14:45:00 CEST | Press release
Teva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus® (ocrelizumab), including both intravenous and subcutaneous formulations.Agreement advances Teva’s Pivot to Growth strategy by expanding its biosimilars pipeline through strategic collaborations.Agreement reflects both companies’ commitment to broadening access to biologic medicines. Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven biosimilar development expertise with Teva’s commercial footprint and capabilities. This press release features multimedia. View the full release here: https://www.bus
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom